Cue Biopharma Inc reports results for the quarter ended September 30 - Earnings Summary
15/11/2024 14:10
* Cue Biopharma Inc CUE.OQ reported a quarterly adjusted
loss
of 17 cents per share for the quarter ended September 30,
higher than the same quarter last year, when the company
reported EPS of -24 cents. The mean expectation of
five analysts for the quarter was for a loss of 19 cents per
share. Wall Street expected results to range from -22 cents
to -17 cents per share.
* Revenue rose 58.9% to $3.34 million from a year ago;
analysts
expected $1.52 million.
* Cue Biopharma Inc's reported EPS for the quarter was a
loss
of 17 cents.
* The company reported a quarterly loss of $8.66 million.
* Cue Biopharma Inc shares had risen by 98.1% this
quarter and
lost 43.2% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 21.7%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 5 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "strong buy"
Wall Street's median 12-month price target for Cue Biopharma Inc
is $4.00
This summary was machine generated from LSEG data November 15 at
02:10 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.19 -0.17 Beat
Jun. 30 2024 -0.28 -0.20 Beat
Mar. 31 2024 -0.28 -0.25 Beat
Dec. 31 2023 -0.28 -0.29 Missed